First human test of CSL040 shows promise for immune disorders
NCT ID NCT05937581
First seen Feb 03, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-stage study tested a new drug, CSL040, in 62 healthy adults to see if it is safe and how the body processes it. The goal is to gather information for future studies in people with immune system disorders. No treatment benefit was expected for participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COMPLEMENT-MEDIATED DISORDERS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Nucleus Network Pty Ltd
Herston, Queensland, 4006, Australia
Conditions
Explore the condition pages connected to this study.